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Systemic inflammation is associated with impaired lung function. Studies, most cross-
sectional, report a stronger association between systemic inflammation and lung function
impairment in men than women. The aim was to evaluate gender differences in the longitu-
dinal association between systemic inflammation and lung function.
We used data from randomly chosen residents of Reykjavı´k, born 1940e54, who were inves-
tigated in three stages: Baseline (1973e75; 1983e85) and follow-up (2001e03). The partici-
pants (n Z 1049, 574 women) had a mean age of 28  6 years at baseline and mean follow-
up time of 27  4 years. At each stage lung function (FEV1 and FVC) and C-reactive protein
(CRP) were evaluated.
Change in FEV1 (pZ 0.04) and FVC (pZ 0.01) was associated with baseline CRP in men but
not in women. In the multiple variable analysis, CRP at baseline was associated with a decline
in FEV1 (3.1 mL/year, 95% CI: 5.1, 0.99) and FVC (2.5 mL/year, 95% CI: 4.4, 0.65) in
men but not in women. Similarly during follow-up, change in CRP, standardised to 1SD, was
associated with a decline in FEV1 (0.19 mL/year, 95% CI: 0.30, 0.07) and FVC
(0.11 mL/year, 95% CI: 0.22, 0.01)) in men but not in women.6110000, þ46 735856450 (mobile); fax: þ46 18 6110228.
r@medsci.uu.se (I.S. O´lafsdo´ttir).
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92 I.S. O´lafsdo´ttir et al.This prospective study confirms a stronger association between systemic inflammation and
lung function decline in men than in women. This may indicate a gender difference in the
mechanisms of lung function decline.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Accelerated decline in lung function is associated with both
morbidity and mortality. Lung function parameters, such as
forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC), are associated with increased cardiovas-
cular morbidity and mortality1,2 and are inversely associ-
ated with levels of inflammatory serum proteins.3 C-
reactive protein (CRP) is related to both reduced lung
function,4 faster rate of FEV1 decline and cardiovascular
disease.5 CRP is an acute-phase reactant, produced by the
liver in response to interleukin-6, and is a sensitive marker
of systemic inflammation.6 Higher levels of CRP are asso-
ciated with decline in FEV1
7,8 but when evaluating the
longitudinal association with lung function decline the
results are less consistent. In the four prospective studies
to date7,9e11 all have reported an inverse association of CRP
and lung function at baseline but only two studies report
a longitudinal association between change in CRP and
change in lung function.7,11
Two cross-sectional population-based studies report that
CRP is associated with lower lung function in men but not in
women.12,13 The same gender difference is reported in
a population-based study,14 where there was an association
of poor lung function and higher levels of matrix
metalloproteinase-9 (MMP-9) and tissue inhibitor of
metalloproteinase-1 (TIMP-1) in 888 elderly subjects. These
associations may implicate that men’s lung function
appears more affected by the inflammatory process than
women’s lung function. However, few prospective studies
have assessed this gender difference. One study on young
Danish adults (20e29 years old) with 9 years follow up,
found change in FEV1 was larger in men with highest CRP
values compared with women, and higher CRP at 20 years
was associated with FEV1 decline in men but not women.
15
The novelty of the present study is a long follow-up time
and wide age range in a homogenous adult population. The
aim of this investigation was to study possible gender
differences in the longitudinal association between CRP and
lung function.Figure 1 Flow diagram defining baseline and follow-up
groups. Age is expressed as mean  SD.Methods and materials
Participants and study design
The Reykjavik Study of the Young, a longitudinal
population-based study, was conducted in three stages
between 1973 and 2003, and recruited 2147 participants
(the sum of participants who participated in all three
stages) aged 25e62 years of age. The first stage took part in
1973e74, the second stage was in 1983e1985, and the third
stage was in 2001e2003. This study is based on a subset of
the Reykjavı´k Study of the Young consisting of a randomsample of individuals born in 1940e1954 who lived in the
greater Reykjavı´k area in 1973. The study was approved by
the Icelandic National Bioethics Committee (nr.VSN-01-040)
and Data Protection Authority (nr.2001070603).
The present study focused on the pulmonary part of the
database.16 The main objective was to evaluate gender
differences when comparing prospectively the association
of lung function and systemic inflammation. Nurses
administered questionnaires, made physical measure-
ments, performed spirometry and collected venous blood
samples after an overnight fast. Subjects who participated
both at baseline (either the first or the second stage) and at
follow-up (third stage), and for whom two serum samples
and an acceptable lung function testing were available,
were included in the study (Fig. 1), in all 1049 subjects. No
subject participated in both the first and second stage.Data collection
Lung function measurements
Spirometry was performed with a Vitalograph (Vitalograph
Ltd., Buckingham, UK) at each stage. One machine was
used up until 1974, a second until 1983, and a third
throughout the remainder of the study. Each machine was
calibrated regularly with a litre syringe. FEV1 and FVC were
measured, and the best of three manoeuvres was used.
Smoking exposure
Smoking status was recorded at each stage and participants
were divided at baseline into “never smokers”, “ex-
smokers” and “current” smokers. At each stage in the
study, smoking was evaluated and the participants were
classified at the end of follow-up as “never-smokers”, “ex-
smokers” (stopped smoking before baseline), “quitted
smoking” (if participant stopped smoking during follow-up),
“started smoking” (if the participant started smoking
during the follow-up period), and “continuous smoker” (if
CRP is associated with lung function decline in men 93participant smoked at all stages of the study). The number
of pack years was calculated.
Clinical measurements
Body Mass Index (BMI) was calculated as weight in kilograms
divided by the square of height in metres.
Comorbidities and physical activity
Hypertension was defined as a positive answer to the
question “Have you ever sought a doctor because of
hypertension?” while diabetes was defined as answering
‘yes’ to the question “Do you have or have you ever had
diabetes?” Ischemic heart disease was defined as a positive
answer to the question “Have you ever been treated in
a hospital because a heart disease?” or answering ‘yes’ to
the question “Are you regularly seeing a doctor because of
angina pectoris?” Participants that answered ‘yes’ to the
question “Have you (since the age of 20) regularly partici-
pated in any sport or exercises?” were defined as being
physical active.
Venous blood samples
At each stage of the study venous blood samples were ob-
tained, serum samples separated by centrifugation and
stored at 20 C for subsequent analysis. These samples
were later defrosted at the end of the follow-up period and
highly sensitive CRP levels were determined by a commer-
cially available latex-enhanced immunoturbidimetric assay
and a Roche Hitachi 911 analyser (Roche Diagnostics, Indi-
anapolis, IN). The lower detection limit of the assay was
0.1 mg/L. Two internal control specimens provided by the
reagent manufacturer were measured in each batch of
samples. The total coefficient of variation for CRPTable 1 Characteristics of study subjects (mean  SD).
Men (n Z 475)
Age (year) 28  6
CRPa (mg/L) 0.63 (0.57, 0.70)
Change in CRP per 1 SD 1.0  7.2
FEV1 (L) 4.10  0.63
FVC (L) 4.90  0.58
FEV1 change (mL/year) 14  19
FVC change (mL/year) 6.8  21
BMI (kg/m2) 23.1  2.8
BMI change (kg/m2) 3.8  3.0
Smoking habits (%)
Never smokers 29.8
Ex smokers 11.8
Quitted smoking 34.8
Started smoking 3.9
Continuous smoker 19.7
Pack years 6.2  8.0
Comorbidities (N (%))
Hypertension 10 (2.1%)
Ischemic heart disease 8(1.7%)
Diabetes mellitus 1 (0.2%)
Physically active 164 (34.5%)
a Geometric mean (95% CI).measurements of the internal controls was 1.1% at
a concentration of 3.73 mg/L and 1.9% at a concentration of
0.68 mg/L.
Statistical analyses
Statistical analyses were performed with STATA 9 software
(Stata Corp., Texas, USA). Study characteristics were
summarised with continuous variables presented as
means  SD and categorical variables summarised as
percentages. CRP was log transformed to obtain normal
distribution. T-test and Chi squared test were used for
comparing men and women. Simple and multiple linear
regressions were used when analysing determinants of
change in lung function. Annual change in FEV1 and FVC was
calculated as the difference between observed lung func-
tion values divided by the duration of follow-up in years.
These analyses were adjusted for BMI, change in BMI, pack
years, age, age2 and height. Quartiles of baseline CRP
values were calculated separately for men and women. CRP
and change in CRP was standardised to one standard devi-
ation (1 SD) in all regression models. Change in CRP was
calculated as the difference between follow-up and base-
line CRP values. Gender interactions between CRP and lung
function was investigated by combining both men and
women in one model. Statistical significance was deter-
mined at a p-value <0.05.
Results
Participant characteristics (n Z 1049) are presented in
Table 1. The mean age at baseline was 28  6 years (ageWomen (n Z 574) p-Values
28  5 0.30
0.88 (0.80, 0.97) <0.0001
1.7  6.9 0.0001
2.90  0.54 <0.0001
3.53  0.49 <0.0001
9.3  18 <0.0001
6.2  16 0.76
22.1  3.1 <0.0001
5.1  3.6 <0.0001
0.01
38.6
11.2
25.6
5.0
20.7
5.2  6.7 0.02
14 (2.4%) 0.72
4 (0.7%) 0.13
0 0.27
132 (23%) <0.001
Figure 2 Association between CRP at baseline and change in
FEV1 (mL/year) in both men and women. The CRP levels are
divided separately into quartiles for men and women.
94 I.S. O´lafsdo´ttir et al.range 19e45 years). The mean follow-up time was 27  4
years, with a variation range of 16e30 years. Women had
a higher CRP at baseline, higher CRP increase and higher
BMI increase during follow-up; whereas, men had a higher
BMI at baseline and a steeper FEV1 decline than women
(Table 1).
Non-participants
At follow-up, the participation rate was 63%. The non-
participants were more likely to be smokers at baseline
(60.1 vs. 50.5%: p < 0.0001), and had higher BMI (23.0 vs.
22.7 kg/m2: p Z 0.03) than participants. However, the
difference in BMI was non-significant when stratified for
gender, as non-responders were slightly more often men
(50.7 vs. 45.3%: p Z 0.08) than the responders. No differ-
ence was found for age or CRP values.Figure 3 Association between CRP at baseline and change in
FVC (mL/year) in both men and women. The CRP levels are
divided separately into quartiles for men and women.Univariate analyses
The changes in both FEV1 and FVC in relation to CRP levels,
expressed as quartiles, are presented in Figs. 2 and 3. A
larger lung function decline was associated with increasing
baseline CRP levels in men but not women.
Multivariate analyses
Higher CRP at baseline and higher CRP increase during
follow-up was related to a faster decline in FEV1 (Table 2)
and FVC (Table 3) in men but not women. Increased BMI was
independently associated with a faster decline in FVC in
both sexes, and a faster decline in FEV1 in women, but not
in men. Pack years smoked between the surveys was an
independent predictor of lung function decline in both men
and women. The associations between CRP and lung func-
tion remained unchanged after adding in smoking status as
an additional independent variable (data not shown).
A significant gender interaction was found regarding the
relationship between baseline CRP and change in FEV1
(p Z 0.02) and FVC (p Z 0.002) as well as change in CRP
and FEV1 (p Z 0.04) and FVC (p Z 0.01), respectively.
Discussion
This longitudinal population-based study indicated that
males had a stronger inverse association between CRP and
change in lung function parameters FEV1 and FVC, than
women.
The gender difference observed is reported in several
studies,12e15 of which most are cross-sectional. The first
study to report this gender difference was based on 1237
subjects (28e56 years old) from three different centres in
the ECRHS (European Community Respiratory Health
Survey) study.12 It reports a larger negative association
between CRP and FEV1 in men than women and a larger
FEV1 decline in men with higher CRP levels but no associ-
ation in women. In the Icelandic BOLD (Burden of
Obstructive Lung Disease) study,13 which was based on 758
subjects (mean age (SD) 57.7years (12.7), an association
was found between CRP and both FEV1 and FVC in men, but
not women. In a prospective study by Rasmussen et al.15
the relationship between CRP and lung function in a pop-
ulation-based cohort of young Danish adults (20e29 years
old) was investigated and the association between inflam-
mation and decline in FEV1 and FVC was found to only be
significant in males. The same gender difference is re-
ported in an elderly population (70 years old) when evalu-
ating MMP-9 and TIMP-1.14
These gender differences are not easily explained,
although hormonal differences in men and women are one
possible explanation. Lung function deteriorates with age
in both men and women, but hormone replacement therapy
(HRT) is associated with better FEV1 and FVC in elderly
women,17 whereas, menopause is associated with poorer
lung function and more respiratory symptoms.18 Analysis of
HRT at the follow-up stage in our study revealed that HRT
was relatively common (40%) in women over 50 years of
age, but its use in younger women and at baseline stages
was insignificant. The frequency of HRT use probably
Table 2 The association of change in FEV1 in men and women with CRP (expressed per 1 SD), age, age
2, height, BMI and pack
years.
Change in FEV1 (in mL/year)
Men Women
Changea (95% CI) p-Value Changea (95% CI) p-Value
CRP at baseline 3.1 (5.1, 0.99) 0.004 0.81 (0.70, 2.3) 0.29
Change in CRP 0.19 (0.30, 0.07) 0.001 0.01 (0.10, 0.10) 0.95
Age 2.1 (7.8, 3.4) 0.45 5.7 (11, 0.45) 0.03
Age2 0.01 (0.05. 0.08) 0.67 0.06 (0.01, 0.12) 0.09
Height 0.32 (0.61, 0.03) 0.03 0.13 (0.39, 0.14) 0.35
BMI at baseline 0.25 (0.41, 0.90) 0.46 0.30 (0.79, 0.19) 0.22
Change in BMI 0.51 (1.1, 0.10) 0.10 0.82 (1.2, 0.42) <0.0001
Pack years during follow-up 0.19 (0.33, 0.05) 0.009 0.17 (0.28, 0.05) 0.005
a Adjusted for all the variables in the table.
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study (and follow-up), as it was considered to reduce
coronary risk, although later trials suggested a small net
harm, which implemented its use for mainly climacteric
complaints. HRT elevates CRP levels, but not IL-6 or other
acute phase reactants.19 However, HRT use was considered
an unsatisfactory explanation for the gender difference
identified in this study, as the difference was found both for
CRP at baseline and for change in CRP.
Menopause is associated with rapid onset of the meta-
bolic syndrome with more central body fat, a shift to
a more atherogenic lipid profile, increased levels of low
density lipoproteins and triglycerides.20 The increase in
visceral adiposity is associated with increased serum
inflammatory markers.21 The quantity and distribution of
body fat influences CRP more in women than in men, as
women with increasing abdominal fat mass have a larger
increase in CRP.22 Therefore, the gender difference in
adiposity may be another contributing factor, as CRP levels
are positively associated with adiposity23 and males
generally accumulate more abdominal body fat, whereas,
premenopausal women develop larger lower body fat.
Thus, it could be speculated whether the deterioration in
lung function is attributable to the loss of the hormonal
protective environment and the negative effects ofTable 3 The association of change in FVC in men and women w
years.
Change in FVC (in mL/year)
Men
Changea (95% CI)
CRP at baseline 2.5 (4.4, 0.65)
Change in CRP 0.11 (0.22, 0.01)
Age 2.1 (7.8, 3.7)
Age2 0.003 (0.07, 0.07)
Height 0.02 (0.32, 0.27)
BMI at baseline 0.83 (1.5, 0.15)
Change in BMI 1.9 (2.5, 1.3)
Pack years during follow-up 0.28 (0.43, 0.14)
a Adjusted for all the variables in the table.different fat distribution. In our study we only had BMI
measurements but not waist circumference which might
have given valuable information regarding abdominal fat
distribution.
Women had higher CRP both at baseline and follow-up,
but interestingly they had smaller lung function decline.
Smoking is associated with increased systemic inflamma-
tion12 but the adult lung function of females exposed to
smoking in utero appears less affected than male lung
function, who have a significant reduction in FEV1 that is
not seen in adult women.24 Sex hormones are important
regulators of foetal lung development25 and it is possible
different lung growth pathways in men and women respond
differently to the effects of smoking, due to different
susceptibility to the inflammatory process, even at this
early stage in life. We found no difference in comorbidities
between men and women but men were more physically
active than women.
We report that CRP was negatively correlated to both
FEV1 and FVC in both cross-sectional and longitudinal
analyses in men but not women. The results for men
supports previous cross-sectional findings of an inverse
relationship between CRP and FEV1,
3,12,26,27 and, CRP and
FVC.27,28 Four prospective studies7,9e11 have evaluated CRP
and lung function and all reported an inverse association ofith CRP (expressed per 1 SD), age, age2, height, BMI and pack
Women
p-Value Changea (95% CI) p-Value
0.008 0.11 (1.1, 1.3) 0.86
0.03 0.01 (0.07, 0.09) 0.77
0.48 5.2 (9.6, 0.92) 0.02
0.94 0.05 (0.003, 0.10) 0.07
0.88 0.12 (0.09, 0.34) 0.26
0.02 0.89 (1.30, 0.49) <0.0001
<0.0001 1.1 (1.4, 0.74) <0.0001
<0.0001 0.20 (0.29, 0.10) <0.0001
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are not univalent regarding their longitudinal conclusions.
Two studies,7,11 report an association between change in
CRP and change in lung function whereas, in the other two
studies,9,10 this association was not found. Our findings for
men, supported Shaaban et al.7 and Bolton et al.11 who
found CRP is negatively correlated to both FEV1 at baseline
and to FEV1 decline in the longitudinal analysis.
Several longitudinal population studies have reported
rate of FEV1 decline and reduced lung function to be
stronger associated with smoking in men than women29e31
whereas others have not found this gender differ-
ence.32e35 Higher CRP levels are associated with smoking in
both men and women,36 although some gender difference
exists. Male smokers seem to have a more generalized
inflammatory reaction with elevation of CRP, fibrinogen,
white-blood count and plasma viscosity; whereas women
only have elevation of white-blood cells and fibrinogen.37
Chinn et al. studied the effects of smoking cessation and
weight gain on lung function in 6654 subjects, and reported
a significantly faster rate of lung function decline in rela-
tion to weight gain in men than women.38 This might be
attributed to the same gender difference we report in the
association of CRP and impaired lung function. That is, the
association of systemic inflammation induced by smoking is
stronger in men than women. In our study pack years
smoked between the surveys was an independent predictor
of lung function decline in both men and women also after
adjusting for CRP. We therefore do not believe that the
gender differences regarding CRP and change in lung
function in the present study are caused by residual con-
founding by tobacco smoking.
Infections affect systemic inflammation, as acute
infections can cause spikes of 10,000 fold increase in CRP39
and chronic infections may drive CRP elevation. We do not
believe this to be a likely explanation to the results in
a population-based study, as CRP within the individual,
within a year-to-year basis, is considered as stable as total
cholesterol and systolic blood pressure.40 Furthermore, two
of the cross-sectional studies12,13 reporting this gender
difference, attempted to minimalise the effect of acute
infections by asking subjects with recent upper respiratory
infections to postpone spirometry until they had recovered.
The strengths of this study are the long follow-up period
and repeated serum CRP measurements from all stages of
the study, which were stored and measured at the same
laboratory. Furthermore, as the randomly selected study
population was chosen from the national registry, it was
likely to be representative of the general population.
The limitations of our study merit some attention.
Firstly, the lung function measurements were taken pre-
bronchodilator and the best of three attempts accepted
without other quality assurance measures. Because we lack
post-bronchodilatory values we are unable to look at
associations between CRP and development of COPD. It
should also be noted that the annual change in FEV1 and
FVC was smaller than expected which also may have been
related to methodological issues with the spirometry.
Secondly, participation may be affected by potential bias
factors such as survival, non-migration and motivation to
participate. Regarding lung function the healthy survivor
effect indicates that those participants lost to follow-up(i.e. likely deceased) are more likely to have had worse
lung function, been heavier smokers and suffered from
concomitant cardiovascular disease or diabetes. Our anal-
ysis of non-participants at follow-up supports this as
smoking was associated with non-participation. However,
comorbidities were so rare at baseline, due to participants
young age, that we were not able to confirm this associa-
tion. Non-responders can present a problem, but at follow-
up in this study, there was no difference in baseline CRP
values between participants and non-participants. Thirdly,
participants were not asked whether they had recent
respiratory or other infections. In our analysis the CRP
measurements had a range of 0.1e72.6. Of those eight had
CRP higher than 20. All results were unchanged if those
were eliminated from the data.
In conclusion, this longitudinal population-based study
confirms the association between elevated CRP and decline
in lung function. However, this association was only found
in men. This may imply that different mechanisms cause
lung impairment in men than women. The nature of this
gender difference is unclear and further investigations are
needed.
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